Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates.

Batist, Gerald; Carney, D.N.; Cowan, Kenneth H.; Veach, Stephen R.; Gilliom, M; Bunn, Paul A.; Ihde, Daniel C.

doi:10.1200/jco.1986.4.6.982

Cited by 34 publications

(8 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy with a platinum-based two drug combination has been used as a standard treatment for SCLC since the development of cisplatin and etoposide in the 1980's. 1 Despite the excellent sensitivity of small cell lung cancer (SCLC) to chemotherapy and high response rates, tumor relapse is an often an unavoidable fact. Therefore, to develop a more attractive SCLC treatment, new drug cares regimens are needed which combine with cisplatin.…”

Section: Introductionmentioning

confidence: 99%

C609T polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin

Kimura

Suzumura

Kira

et al. 2013

Clin Med Insights Oncol

View full text Add to dashboard Cite

Background:Amrubicin hydrochloride (AMR) is a key agent for lung cancer. NADPH quinone oxidoreductase 1 (NQO1) metabolizes the quinone structures contained in both amrubicin (AMR) and amrubicinol (AMR-OH). We hypothesized that NQO1 C609T polymorphism may affect AMR-related pharmacokinetics and clinical outcomes.Methods:Patients received AMR doses of 30 or 40 mg/m2/day on days 1–3. Plasma sampling was performed 24 hours after the first and third AMR injections. Concentrations of AMR and AMR-OH were determined by HPLC and the NQO1 C609T polymorphism was assayed by RT-PCR.Results:A total of 35 patients were enrolled. At a dose of 40 mg/m2, the T/T genotype exhibited a tendency toward a relationship with decrease concentrations of AMR-OH on days 2 and 4. The genotype also showed a significant decrease of hematological toxicities (P < 0.05).Conclusions:NQO1 C609T polymorphism had a tendency of correlation with the plasma concentrations of AMR-OH, and thereby had significant correlations with hematologic toxicities.

show abstract

Section: Introductionmentioning

confidence: 99%

C609T polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin

Kimura

Suzumura

Kira

et al. 2013

Clin Med Insights Oncol

View full text Add to dashboard Cite

show abstract

“…Overall survival was 8.1 months for patients with limited disease and 4.9 months for those with extensive disease. On the other hand, the report by Batist et al of 29 patients showed only a 12% response rate, median duration of response 3.5 months, and median survival for all patients of 3 months [21]. All patients in the latter study had received prior chemotherapy with a six-drug regimen, and 24 of 29 (83%) had received chest irradiation and had a median interval of only 3 weeks from prior chemotherapy.…”

Section: Disc U Wonmentioning

confidence: 82%

Phase II trial of etoposide and cisplatin for refractory small cell lung cancer: A cancer and leukemia group B study

Graziano

Lee

Propert

et al. 1990

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

A phase II trial of etoposide and cisplatin for patients with previously treated small cell lung cancer was carried out by CALGB from June 1983 to May 1984. Thirty-five evaluable patients who had failed one prior chemotherapy regimen were treated with etoposide 80 mg/m2 and cisplatin 20 mg/m2 days 1-5 every 3 weeks. Objective responses were seen in 7 patients (20%) with 1 complete response and 6 partial responses. The median duration of response was 5.1 months. Fifteen patients (43%) had stable disease. Overall survival was 49% at 6 months and 14% at 1 year. The median survival was 6 months. Toxicity was mainly hematologic with severe and life-threatening leukopenia and thrombocytopenia seen in 71% and 66% of patients, respectively. Two treatment-related deaths caused by infection were seen. This cooperative group study fails to confirm the high response rates previously reported in institutional pilot studies.

show abstract

“…34 In other studies, 40% 35 and 50% 36 response rates were observed for PE; however, there is an issue that the percentages of sensitive and refractory relapse were not presented in those studies. In fact, only a 12% response rate was observed in the study conducted by Batist et al 37 In the study, the median time since the last chemotherapy was 3 weeks (range, 1-24), suggesting that the majority of patients had refractory relapse. Porter et al…”

Section: Combination Chemotherapymentioning

confidence: 85%

Second-line chemotherapy for small-Cell Lung Cancer (SCLC)

Kim¹,

Mishima²

2011

Cancer Treatment Reviews

View full text Add to dashboard Cite

Although small-cell lung cancer (SCLC) generally shows an excellent response to initial chemotherapy, most patients finally relapse and salvage chemotherapy is considered. Usually, the response to salvage chemotherapy significantly differs between sensitive and refractory relapse. Sensitive relapse is relatively chemosensitive and re-challenge with the same drugs as used in the initial chemotherapy has been used historically, while refractory relapse is extremely chemo-resistant and its prognosis has been abysmal. To date, a number of clinical trials have been carried out for relapsed SCLC; however, the number of randomized trials is quite limited. At present, topotecan is the only drug approved by the US Food and Drug Administration for relapsed SCLC, and is considered the standard second-line chemotherapy in many countries. More recently, amrubicin has also shown more favorable antitumor activity, and is the most promising at present. Unfortunately, targeted agents have failed to demonstrate effectiveness for SCLC. Better understanding of the molecular mechanisms is clearly needed.

show abstract

Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates.

Cited by 34 publications

References 4 publications

C609T polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin

C609T polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin

Phase II trial of etoposide and cisplatin for refractory small cell lung cancer: A cancer and leukemia group B study

Second-line chemotherapy for small-Cell Lung Cancer (SCLC)

Contact Info

Product

Resources

About